Yu Shyr

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Power and sample size calculation for non-inferiority trials with treatment switching in intention-to-treat analysis comparing RMSTs	2024	A. Shih Chih–Yuan Hsu Yu Shyr
+	Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Data S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Data S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Table S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S4 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Data S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Data from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Table S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+ PDF Chat	Power and sample sizes estimation in clinical trials with treatment switching in intention-to-treat analysis: a simulation study	2023	Lejun Deng Chih–Yuan Hsu Yu Shyr
+ PDF Chat	Power and sample sizes estimation in clinical trials with treatment switching in intention-to-treat analysis: a simulation study	2022	Lejun Deng Chih–Yuan Hsu Yu Shyr
+ PDF Chat	Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit	2022	Emily Pei-Ying Lin Chih–Yuan Hsu Jeng-Fong Chiou Lynne D. Berry Leora Horn Paul A. Bunn James Chih‐Hsin Yang Pan‐Chyr Yang Alex A. Adjei Yu Shyr
+ PDF Chat	MITI minimum information guidelines for highly multiplexed tissue images	2022	Denis Schapiro Clarence Yapp Artem Sokolov Sheila M. Reynolds Chen Yuan Damir Sudar Yubin Xie Jeremy Muhlich Raquel Arias-Camison Sarah Arena
+ PDF Chat	Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results With Long-term Survival	2021	Chih–Yuan Hsu Emily Lin Yu Shyr
+ PDF Chat	Biomarker Discovery and Validation: Statistical Considerations	2021	Fang‐Shu Ou Stefan Michiels Yu Shyr Alex A. Adjei Ann L. Oberg
+	The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic	2020	Derek Shyr Yu Shyr
+	What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?	2020	Yu Shyr Derek Shyr
+	Changing paradigm in oncology clinical trials: Cox-TEL—Adjustment made ready for early crossover and tail tale.	2020	Emily Pei-Ying Lin Chih–Yuan Hsu Pan‐Chyr Yang Yu Shyr
+ PDF Chat	P2.04-50 Advanced Statistical Approach Tells the Difference: Taylor-Expansion Adjustment for Survival Analyses in Immunotherapy Trials	2019	Chih–Yuan Hsu Emily Pei-Ying Lin Yu Shyr
+	Design and Conduct of Clinical Trials for Breast Cancer	2017	V. Suzanne Klimberg Yu Shyr Thomas G. Wells
+	Adaptive clinical trials: overview 1	2017	Yu Shyr
+	Adaptive clinical trials: conclusion and future directions	2017	Yu Shyr
+	Adaptive clinical trials: overview 2	2017	Yu Shyr
+	Statistical Consideration in Predictive and Prognostic Markers	2017	Fei Ye Yu Shyr
+	Functional data classification using covariate-adjusted subspace projection	2017	Pai-Ling Li Jeng‐Min Chiou Yu Shyr
+	Impact of Preference and Equivocators on Opinion Dynamics with Evolutionary Game Framework	2015	Yong Deng Zhen Wang Qi Liu Yong Deng Yu Shyr
+	Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates	2015	Pei‐Fang Su Yu Shyr Chung-I Li
+	Impact of Preference and Equivocators on Opinion Dynamics with Evolutionary Game Framework	2015	Yong Deng Zhen Wang Liu Qi Yong Deng Yu Shyr
+	The Design of and<i>R</i>Control Charts for Skew Normal Distributed Data	2014	Chung‐I Li Nan-Cheng Su Pei‐Fang Su Yu Shyr
+ PDF Chat	Sample size determination for paired right-censored data based on the difference of Kaplan–Meier estimates	2014	Pei‐Fang Su Chung‐I Li Yu Shyr
+	Data Safety Monitoring Boards	2013	Kamran Idrees Fei Ye Yu Shyr Nipun B. Merchant
+ PDF Chat	Analysis of covariance with pre-treatment measurements in randomized trials under the cases that covariances and post-treatment variances differ between groups	2011	Takashi Funatogawa Ikuko Funatogawa Yu Shyr
+ PDF Chat	Analyzing survival curves at a fixed point in time for paired and clustered right-censored data	2010	Pei‐Fang Su Yunchan Chi Chung‐I Li Yu Shyr Yi-De Liao
+	Design and Analysis of Clinical Trials with Time‐to‐Event Endpoint edited by PEACE, K. E.	2010	Yu Shyr
+	Design and Conduct of Clinical Trials for Breast Cancer	2009	Yu Shyr
+ PDF Chat	A nonparametric smoothing method for assessing GEE models with longitudinal binary data	2008	Kuo‐Chin Lin Yi‐Ju Chen Yu Shyr
+	Balanced two-stage designs for phase II clinical trials	2007	Fei Ye Yu Shyr
+	Sample size determination for the two-stage design of a phase II cancer clinical trials with correlated unbalance binary endpoints	1998	Yu Shyr Brenda P. Nicholson David H. Johnson
+	A canonical form of anderson's classification statistic	1998	Yu Shyr
+	Stepwise canonical analysis in categorical data	1997	Yu Shyr Anant M. Kshirsagar
+	Some aspects of canonical correlation analysis.	1994	Yu Shyr

Common Coauthors

Coauthor	Papers Together
Alex Koong	12
Ruitao Lin	12
Ryan Sun	12
Ramez Kouzy	12
Joseph Abi Jaoude	12
Alexander D. Sherry	12
Timothy A. Lin	12
Tomer Meirson	12
J. Jack Lee	12
Molly B. El Alam	12
Clifton D. Fuller	12
Roshal R. Patel	12
Ying Yuan	12
Ethan B. Ludmir	12
Sonal S. Noticewala	12
Zachary R. McCaw	12
Christine Lin	12
Charles R. Thomas	10
Chih–Yuan Hsu	7
Pei‐Fang Su	4
Chung‐I Li	3
Emily Pei-Ying Lin	3
Zhen Wang	2
Fei Ye	2
Charles R. Thomas	2
Derek Shyr	2
Alex A. Adjei	2
Lejun Deng	2
Pan‐Chyr Yang	2
Yong Deng	2
Marc D. Ryser	1
Dinh Diep	1
Qiuyin Cai	1
Sandro Santagata	1
Ken S. Lau	1
Gordon B. Mills	1
Young Hwan Chang	1
Tuhin K. Guha	1
Eliezer R. Van Allen	1
Ethan Baker	1
Genevieve M. Boland	1
Rozelle Laquindanum	1
Cody N. Heiser	1
Kai Tan	1
Giorgio Gaglia	1
Rachel E. Factor	1
Chia‐Hui Chen	1
Nipun B. Merchant	1
Joseph M. Chan	1
Jianjiong Gao	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Correcting for non-compliance in randomized trials using rank preserving structural failure time models	1991	James M. Robins Anastasios A. Tsiatis	3
+	One-Sample Multiple Testing Procedure for Phase II Clinical Trials	1982	Thomas R. Fleming	3
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	3
+	The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent	1961	Edmund A. Gehan	3
+ PDF Chat	Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study	2011	James P. Morden Paul C. Lambert Nicholas Latimer Keith R. Abrams Allan Wailoo	3
+ PDF Chat	RISE OF THE CENTRIST: FROM BINARY TO CONTINUOUS OPINION DYNAMICS	2008	George A. Baker J. P. Hague	2
+	Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method	2016	Jin Zhang Cong Chen	2
+	The structure and dynamics of multilayer networks	2014	Stefano Boccaletti Ginestra Bianconi Regino Criado Charo I. del Genio Jesús Gómez‐Gardeñes Miguel Romance I. Sendiña–Nadal Z. Wang Massimiliano Zanin	2
+	Interim analysis in clinical trials	1991	P. Armitage	2
+ PDF Chat	Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome	2013	Patrick Royston Mahesh Parmar	2
+ PDF Chat	Estimation in a Cox Proportional Hazards Cure Model	2000	Judy P. Sy Jeremy M. G. Taylor	2
+ PDF Chat	Phase Transitions and Spatio-Temporal Fluctuations in Stochastic Lattice Lotka–Volterra Models	2006	Mauro Mobilia Ivan T. Georgiev Uwe C. Täuber	2
+	A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data	2018	Chih–Yuan Hsu Chen‐Hsin Chen Ken-Ning Hsu Ya-Hung Lu	2
+ PDF Chat	OPINION EVOLUTION IN CLOSED COMMUNITY	2000	Katarzyna Sznajd-Weron J. Szṅajd	2
+	Regression Shrinkage and Selection Via the Lasso	1996	Robert Tibshirani	2
+ PDF Chat	Sample size calculation for the proportional hazards cure model	2012	Songfeng Wang Jiajia Zhang Wenbin Lu	2
+	Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method	2014	Nicholas Latimer Keith R. Abrams Paul C. Lambert Michael J. Crowther Allan Wailoo J.P. Morden RL Akehurst Michael J. Campbell	2
+ PDF Chat	Birth and death in a continuous opinion dynamics model	2008	Timotéo Carletti Duccio Fanelli Alessio Guarino Franco Bagnoli Andrea Guazzini	2
+	A Multiple Testing Procedure for Clinical Trials	1979	Peter C. O’Brien Thomas R. Fleming	2
+ PDF Chat	Using Weighted Kaplan‐Meier Statistics in Nonparametric Comparisons of Paired Censored Survival Outcomes	2001	Susan Murray	2
+	Clinical Trials: A Practical Approach.	1984	Ira Hill Stuart J. Pocock	2
+	Biomarker studies: a call for a comprehensive biomarker study registry	2011	Fabrice André Lisa M. McShane Stefan Michiels David F. Ransohoff Douglas G. Altman Jorge S. Reis‐Filho Daniel F. Hayes Lajos Pusztai	2
+	Longitudinal data analysis using generalized linear models	1986	Kung‐Yee Liang Scott L. Zeger	2
+ PDF Chat	CRITICAL BEHAVIOR IN AN EVOLUTIONARY ULTIMATUM GAME WITH SOCIAL STRUCTURE	2009	Vı́ctor M. Eguı́luz Claudio J. Tessone	2
+ PDF Chat	Model of binary opinion dynamics: Coarsening and effect of disorder	2009	Soham Biswas Parongama Sen	2
+	Nonparametric Estimation from Incomplete Observations	1992	Edward L. Kaplan Paul Meier	2
+ PDF Chat	Weighted Kaplan-Meier Statistics: A Class of Distance Tests for Censored Survival Data	1989	Margaret S. Pepe Thomas R. Fleming	2
+ PDF Chat	Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study	2016	Nicholas Latimer Keith R. Abrams Paul C. Lambert James P. Morden Michael J. Crowther	2
+ PDF Chat	CONTINUOUS OPINIONS AND DISCRETE ACTIONS IN OPINION DYNAMICS PROBLEMS	2008	André C. R. Martins	2
+ PDF Chat	SOCIOPHYSICS: A REVIEW OF GALAM MODELS	2008	Serge Galam	2
+	A mixture model combining logistic regression with proportional hazards regression	1992	Anthony Y. C. Kuk Chen‐Hsin Chen	2
+ PDF Chat	Opinion dynamics model with weighted influence: Exit probability and dynamics	2013	Soham Biswas S. K. Sinha Parongama Sen	2
+	Upstream reciprocity in heterogeneous networks	2010	Akio Iwagami Naoki Masuda	2
+	Forcing a sequential experiment to be balanced	1971	Bradley Efron	2
+ PDF Chat	Cooperation and the Emergence of Role Differentiation in the Dynamics of Social Networks	2005	Vı́ctor M. Eguı́luz Martín Zimmermann Camilo J. Cela‐Conde M. San Miguel	2
+	Repeated assessment of results in clinical trials of cancer treatment	1971	J. L. Haybittle	2
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	2
+ PDF Chat	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis	2014	Hajime Uno Brian Claggett Lü Tian Eisuke Inoue Paul Gallo Toshio Miyata Deborah Schrag Masahiro Takeuchi Yoshiaki Uyama Lihui Zhao	2
+ PDF Chat	Interdependent network reciprocity in evolutionary games	2013	Zhen Wang Attila Szolnoki Matjaž Perc	2
+	Oscillatory dynamics in rock–paper–scissors games with mutations	2010	Mauro Mobilia	2
+ PDF Chat	OPINION FORMATION MODELS BASED ON GAME THEORY	2007	ALESSANDRO DI MARE Vito Latora	2
+ PDF Chat	Evolutionary games with facilitators: When does selection favor cooperation?	2013	Mauro Mobilia	2
+ PDF Chat	Evolutionary games on graphs	2007	György Szabó Gábor Fáth	2
+	Testing for correlation between non-negative variates	1967	P. A. P. Moran	2
+	Balanced two-stage designs for phase II clinical trials	2007	Fei Ye Yu Shyr	2
+ PDF Chat	Participation costs dismiss the advantage of heterogeneous networks in evolution of cooperation	2007	Naoki Masuda	2
+	A Causal Proportional Hazards Estimator for the Effect of Treatment Actually Received in a Randomized Trial with All‐or‐Nothing Compliance	2003	Tom Loeys Els Goetghebeur	2
+	Estimating a treatment effect in survival studies in which patients switch treatment	2002	Michael Branson John Whitehead	2
+ PDF Chat	Ultimate fate of constrained voters	2004	Federico Vázquez S. Redner	2
+ PDF Chat	Evolution of public cooperation on interdependent networks: The impact of biased utility functions	2012	Zhen Wang Attila Szolnoki Matjaž Perc	2